DIPROLENE Drug Patent Profile
When do Diprolene patents expire, and when can generic versions of Diprolene launch?
Diprolene is a drug marketed by Schering and Organon and is included in four NDAs.
The generic ingredient in DIPROLENE is betamethasone dipropionate. There is one drug master file entry for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the betamethasone dipropionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Diprolene
A generic version of DIPROLENE was approved as betamethasone dipropionate by FOUGERA on June 26th, 1984.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DIPROLENE?
- What are the global sales for DIPROLENE?
- What is Average Wholesale Price for DIPROLENE?
Summary for DIPROLENE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 4 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 68 |
| Clinical Trials: | 2 |
| Patent Applications: | 6,489 |
| Drug Prices: | Drug price information for DIPROLENE |
| What excipients (inactive ingredients) are in DIPROLENE? | DIPROLENE excipients list |
| DailyMed Link: | DIPROLENE at DailyMed |
Recent Clinical Trials for DIPROLENE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Cairo University | N/A |
| LEO Pharma | Phase 1 |
Pharmacology for DIPROLENE
| Drug Class | Corticosteroid |
| Mechanism of Action | Corticosteroid Hormone Receptor Agonists |
US Patents and Regulatory Information for DIPROLENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | DIPROLENE | betamethasone dipropionate | CREAM, AUGMENTED;TOPICAL | 019408-001 | Jan 31, 1986 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Organon | DIPROLENE | betamethasone dipropionate | OINTMENT, AUGMENTED;TOPICAL | 018741-001 | Jul 27, 1983 | AB | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Schering | DIPROLENE | betamethasone dipropionate | GEL, AUGMENTED;TOPICAL | 019408-002 | Nov 22, 1991 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Organon | DIPROLENE | betamethasone dipropionate | LOTION, AUGMENTED;TOPICAL | 019716-001 | Aug 1, 1988 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Organon | DIPROLENE AF | betamethasone dipropionate | CREAM, AUGMENTED;TOPICAL | 019555-001 | Apr 27, 1987 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DIPROLENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Schering | DIPROLENE | betamethasone dipropionate | CREAM, AUGMENTED;TOPICAL | 019408-001 | Jan 31, 1986 | 4,482,539 | ⤷ Start Trial |
| Organon | DIPROLENE | betamethasone dipropionate | LOTION, AUGMENTED;TOPICAL | 019716-001 | Aug 1, 1988 | 4,775,529 | ⤷ Start Trial |
| Schering | DIPROLENE | betamethasone dipropionate | GEL, AUGMENTED;TOPICAL | 019408-002 | Nov 22, 1991 | 4,489,070 | ⤷ Start Trial |
| Schering | DIPROLENE | betamethasone dipropionate | CREAM, AUGMENTED;TOPICAL | 019408-001 | Jan 31, 1986 | 4,489,070 | ⤷ Start Trial |
| Organon | DIPROLENE | betamethasone dipropionate | OINTMENT, AUGMENTED;TOPICAL | 018741-001 | Jul 27, 1983 | 4,070,462 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DIPROLENE
See the table below for patents covering DIPROLENE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2999177 | ⤷ Start Trial | |
| Australia | 509635 | ⤷ Start Trial | |
| Belgium | 860071 | ⤷ Start Trial | |
| Switzerland | 627652 | Topical ointment | ⤷ Start Trial |
| Germany | 2747631 | ⤷ Start Trial | |
| Denmark | 152171 | ⤷ Start Trial | |
| Denmark | 473177 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
DrugChatter Q&A for DIPROLENE
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch